|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients显示文摘AIM:To investigate whether the evaluation of tumor budding can complement K-RAS analysis to improve the individualized prediction of response to anti-epidermal growth factor receptor based therapies in metastatic colorectal cancer (mCRC) patients. METHODS:Forty-three patients with mCRC treated with cetuximab or panitumumab were entered into this study. According to the Response Evaluation Criteria in Solid Tumors criteria, 30 patients had stable or progressive disease (non-responsive), while 13 patients had a partial response. Tumor buds were evaluated from whole tissue sections stained for pan-cytokeratin, evaluated in the densest region using a 40 × objective and 'high-grade' tumor budding was defi ned as 15 buds/high-power f ield.RESULTS: Tumor buds and K-RAS mutation both correctly classif ied 68% of patients. All patients with K-RAS mutation (n=7) or high-grade tumor budding (n=11) were non-responsive, of which 4 patients had both features. All 13 partial responders were K-RAS wild-type with low-grade tumor budding. Combined, the predictive value of K-RAS and tumor budding was 80%. Additionally, high-grade tumor budding was significantly related to worse progression-free survival [HR (95% CI): 2.8 (1.3-6.0, P=0.008)].CONCLUSION: If confirmed in larger cohorts, the addition of tumor budding to K-RAS analysis may represent an effective approach for individualized patient management in the metastatic setting. | Inti Zlobec Francesca Molinari Vittoria Martin Luca Mazzucchelli Piercarlo Saletti Rosangela Trezzi Sara De Dosso Tatjana Vlajnic Milo Frattini Alessandro Lugli | 2010 | World Journal of Gastroenterology2010，16，38： | 4 |
| 2 | Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus显示文摘 | Di Nicolantonio Federica Arena Sabrina Tabernero Josep Grosso Stefano Molinari Francesca Macarulla Teresa Russo Mariangela Cancelliere Carlotta Zecchin Davide Mazzucchelli Luca Sasazuki Takehiko Shirasawa Senji Geuna Massimo Frattini Milo Ba | 2010 | Journal of Clinical Investigation2010，，8： | 1 |
| 3 | Use of accurate diagnostic criteria may increase incidence of stercoral perforation of the colon显示文摘 | Christoph A. Maurer M.D. Pietro Renzulli M.D. Luca Mazzucchelli M.D. Bernhard Egger M.D. Christian A. Seiler M.D. Prof. Markus W. Büchler M.D | 2000 | Diseases of the Colon & Rectum2000，，7： | 1 |
| 4 | Epithelial neutrophil-activating peptide 78 con centrations are elevated in the peritoneal fluid of women with endometriosis显示文摘 | Michael D Mueller Luca Mazzucchelli Caroline Buri | 2003 | Fertil Steril2003，，1： | 1 |
| 5 | Risk factors of central nervous system relapse in mantle cell lymphoma显示文摘 | Annarita Conconi Silvia Franceschetti Chiara Lobetti-Bodoni Anastasios Stathis Gloria Margiotta-Casaluci Antonio Ramponi Luca Mazzucchelli Francesco Bertoni Michele Ghielmini Gianluca Gaidano Franco Cavalli Emanuele Zucca | 2013 | Leukemia & Lymphoma2013，，9： | 1 |
| 6 | Targeted approaches for HER2 breast cancer therapy: News from nanomedicine?显示文摘About 30% of human breast cancers are human epidermal growth factor receptor 2(HER2)+. This particular biological portrait is characterized by the overexpression of HER2 receptor with the subsequent deregulation of downstream pathways, which control cellular survival and proliferation. The most effective treatment for HER2+cancer is represented by therapy with HER2-targeted agents. Anti-HER2 therapy dramatically improves clinical outcomes, although it shows some limitations in achieving a proper treatment. These drawbacks of HER2-targeted therapy may be overcome with the development of HER2-targeted drug delivery nanodevices. These nanoparticles possess an internal three-dimensional compartimentalization, which allows to combine the specific target recognition with their capability to act as a drug reservoir for the selective delivery of chemotherapics to tumor sites. Moreover, nanoparticles useful in photothermal ablation or in photodynamic therapy have been functionalized in order to match specificity in tumor cell recognition and suitable chemical properties. Here, we summarize the state of the art concerning the HER2+breast cancer and anti-HER2 therapy, in particular deepening the contribution of the nanomedicine. Description of preclinical studies performed with HER2-targeted na-noparticles for HER2+ breast cancer therapy will be preceded by an overview on HER2-targeting molecules and nano-conjugation strategies. Further investigation will be necessary to introduce these nano-drugs in clinical practice; however promising results encourage an upcoming translation of this research for the next future. | Serena Mazzucchelli Marta Truffi Luisa Fiandra Luca Sorrentino Fabio Corsi | 2014 | World Journal of Pharmacology2014，3，4： | 0 |
| 7 | Antiretroviral Therapy through Barriers: A Prominent Role for Nanotechnology in HIV-1 Eradication from Sanctuaries显示文摘 | Fabio Corsi Luca Sorrentino Serena Mazzucchelli Marta Truffi Amedeo Capetti Giuliano Rizzardini Luisa Fiandra | 2016 | Journal of Pharmacy and Pharmacology2016，4，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员